MA28394B1 - Derives d'heteroaryle pour traitement des virus - Google Patents

Derives d'heteroaryle pour traitement des virus

Info

Publication number
MA28394B1
MA28394B1 MA29128A MA29128A MA28394B1 MA 28394 B1 MA28394 B1 MA 28394B1 MA 29128 A MA29128 A MA 29128A MA 29128 A MA29128 A MA 29128A MA 28394 B1 MA28394 B1 MA 28394B1
Authority
MA
Morocco
Prior art keywords
viruses
treatment
heteroaryl derivatives
heteroaryl
derivatives
Prior art date
Application number
MA29128A
Other languages
English (en)
Inventor
Ulrich Schmitz Franz
Botyanszki Janos
Don Roberts Christopher
Original Assignee
Genelabs Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genelabs Tech Inc filed Critical Genelabs Tech Inc
Publication of MA28394B1 publication Critical patent/MA28394B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA29128A 2005-06-24 2006-06-22 Derives d'heteroaryle pour traitement des virus MA28394B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69370005P 2005-06-24 2005-06-24

Publications (1)

Publication Number Publication Date
MA28394B1 true MA28394B1 (fr) 2007-01-02

Family

ID=37499598

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29128A MA28394B1 (fr) 2005-06-24 2006-06-22 Derives d'heteroaryle pour traitement des virus

Country Status (14)

Country Link
US (1) US20060293320A1 (fr)
EP (1) EP1910337A2 (fr)
JP (1) JP2008546802A (fr)
KR (1) KR20080040677A (fr)
CN (1) CN101223161A (fr)
AR (1) AR054797A1 (fr)
AU (1) AU2006261132A1 (fr)
BR (1) BRPI0612124A2 (fr)
CA (1) CA2613261A1 (fr)
MA (1) MA28394B1 (fr)
MX (1) MX2007016144A (fr)
PE (1) PE20070124A1 (fr)
TW (1) TW200726471A (fr)
WO (1) WO2006138744A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1996233A2 (fr) * 2006-02-27 2008-12-03 Gilead Colorado, Inc. Combinaisons thérapeutiques et méthodes pour amélioration cardio-vasculaire et traitement de maladie cardio-vasculaire
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
EP2170882A1 (fr) * 2007-06-26 2010-04-07 Gilead Colorado, Inc. Inhibiteurs d'imidazopyridinyl-thiazolyl-histone désacétylase
NZ602832A (en) * 2008-07-14 2014-04-30 Gilead Sciences Inc Fused heterocyclic hdac inhibitor compounds
AU2009271003A1 (en) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
CA2728228A1 (fr) * 2008-07-14 2010-01-21 Gilead Sciences, Inc. Composes inhibiteurs de l'oxindolyle
AU2009276699A1 (en) * 2008-07-28 2010-02-04 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene histone deacetylase inhibitor compounds
DK2318007T3 (da) 2008-08-15 2013-03-25 N30 Pharmaceuticals Inc Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
HUE031580T2 (en) 2008-08-15 2017-07-28 Nivalis Therapeutics Inc Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
EP2315590B1 (fr) 2008-08-15 2012-09-26 N30 Pharmaceuticals, LLC Inhibiteurs pyrroliques de la s nitrosoglutathion réductase
CA2750565C (fr) 2009-01-30 2015-10-20 Glaxosmithkline Llc Chlorhydrate de n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide cristallin
KR20120031170A (ko) * 2009-06-08 2012-03-30 길리애드 사이언시즈, 인코포레이티드 알카노일아미노 벤즈아미드 아닐린 ｈｄａｃ 저해제 화합물
ES2463826T3 (es) * 2009-06-08 2014-05-29 Gilead Sciences, Inc. Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina
EA020031B1 (ru) * 2009-06-11 2014-08-29 Эббви Бахамаз Лтд. Противовирусные соединения
US8822515B2 (en) 2009-10-16 2014-09-02 University Of Maryland, Baltimore County Heterocyclic benzoxazole compositions as inhibitors of hepatitis C virus
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
TWI508968B (zh) 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
AP2013006734A0 (en) * 2010-09-30 2013-02-28 Boehringer Ingelheim Int Combination therapy for treating HCV infection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE69133617D1 (de) * 1990-04-04 2009-07-23 Novartis Vaccines & Diagnostic Protease von Hepatitis C Virus
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2159639A1 (fr) * 1993-04-02 1994-10-13 Vincent J. Miles Methode pour l'inactivation selective de la replication virale
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US5861267A (en) * 1995-05-01 1999-01-19 Vertex Pharmaceuticals Incorporated Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity
US5759795A (en) * 1996-03-08 1998-06-02 Schering Corporation Assay for determining inhibitors of ATPase
AU726374B2 (en) * 1997-03-05 2000-11-02 University Of Washington Novel screening methods to identify agents that selectively inhibit hepatitis C virus replication
DE69838513T2 (de) * 1997-12-11 2008-07-03 Smithkline Beecham Corp. Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP2335700A1 (fr) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
WO2004009017A2 (fr) * 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulateurs de recepteurs de glucocorticoides et procede associe
GB0307891D0 (en) * 2003-04-04 2003-05-14 Angeletti P Ist Richerche Bio Chemical compounds,compositions and uses
CA2534649A1 (fr) * 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Derives de l'imidazole bicycliques diriges contre les flaviviridae

Also Published As

Publication number Publication date
AU2006261132A1 (en) 2006-12-28
TW200726471A (en) 2007-07-16
KR20080040677A (ko) 2008-05-08
MX2007016144A (es) 2008-03-06
AR054797A1 (es) 2007-07-18
CA2613261A1 (fr) 2006-12-28
US20060293320A1 (en) 2006-12-28
WO2006138744A2 (fr) 2006-12-28
CN101223161A (zh) 2008-07-16
BRPI0612124A2 (pt) 2010-10-19
PE20070124A1 (es) 2007-03-09
WO2006138744A3 (fr) 2007-04-05
JP2008546802A (ja) 2008-12-25
EP1910337A2 (fr) 2008-04-16

Similar Documents

Publication Publication Date Title
MA29097B1 (fr) Composes pour le traitement des infections virales par flaviviridae
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
EP1976516A4 (fr) Traitement de l'hépatite virale
MA29098B1 (fr) Compositions pour le traitement du vhc
NO20052580D0 (no) Blandinger for behandling av infeksjon av Flavivirida viruser
EP1931691A4 (fr) Inhibiteurs d'odcase pour le traitement du paludisme
EP2120566A4 (fr) Composés et compositions pharmaceutiques destinés au traitement d'infections virales
EP2019825A4 (fr) Inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
EP2001516A4 (fr) Vaccins pour des virus provoquant des infections persistantes ou latentes
EP1915054A4 (fr) Derives d'acetaux cycliques de ribonucleosides pour traiter une infection virale d'arn arn dependante
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE533774T1 (de) Neuartige nukleosidanaloge zur behandlung von virusinfektionen
ATE486597T1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
DK1709075T3 (da) Behandling af virusinfektioner
EP1881825A4 (fr) Inhibiteurs de l'intégrase du vih
EP2120988A4 (fr) Traitement de l'infection par le virus de l'hépatite c
PT1299395E (pt) Oxazinoquinolonas uteis para o tratamento de infeccoes provocadas por virus
EP1965827A4 (fr) Traitement d'etats lies a la demyelination
BRPI0612124A2 (pt) derivados de heteroarila para o tratamento de viroses